Journal
MOLECULAR DIAGNOSIS & THERAPY
Volume 24, Issue 4, Pages 433-441Publisher
ADIS INT LTD
DOI: 10.1007/s40291-020-00469-4
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81760544]
- Key Research and Development Program Project of Guangxi Zhuang Autonomous Region [GuikeAB18221007]
- Independent Project of Key Laboratory of Early Prevention and Treatment for Regional High-Incidence Tumor [GKE2019-17]
Ask authors/readers for more resources
Interferon (IFN)-induced transmembrane protein 1 (IFITM1), a member of the IFN-induced transmembrane protein family, is reported to be highly expressed in tumor tissues as well as cancer cell lines, and it is an independent prognostic biomarker for patients with certain tumor types, such as gallbladder carcinoma, esophageal adenocarcinoma, colorectal cancer, and gastric cancer. Moreover, overexpression of IFITM1 promotes tumor cell proliferation, invasion, metastasis, angiogenesis, and therapeutic resistance, including endocrine therapy, chemotherapy, and radiotherapy resistance. Due to these diverse functions of IFITM1 in tumors, targeting IFITM1 may provide a novel strategy for cancer treatment and be highly desirable to improve cancer patient outcomes. Herein, we decipher the role of IFITM1 in cancer in detail.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
